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Recombinant parainfluenza virus 3 (rPIV3) is being developed as a vector to express foreign genes as a bivalent or
multivalent live attenuated virus vaccine. In the present study, we examined the effect of inserted foreign sequence on virus
replication in vitro and in vivo, focusing on the parameter of insert length. In one type of construct, foreign sequence of
increasing length was flanked by PIV3 transcription signals and inserted as an additional gene unit (GU insert) between the
HN and L genes, so that one additional mRNA would be made. In a second type of construct, foreign sequence was inserted
into the downstream NCR (NCR insert) of the HN gene, so that the number of encoded mRNAs remained unchanged. In each
case, the foreign sequence was designed to lack any significant open reading frame, which permitted an evaluation of the
effect of insert length on replication independent of an effect of an expressed protein. The GU or NCR insert sizes ranged
from 168 nucleotides (nt) to 3918 nt. rPIV3s containing GU insertions of up to 3918 nt in length, the largest size tested, were
viable and replicated efficiently at permissive temperatures in vitro, but a reduction in plaque size was seen at 39°C and
40°C. The rPIV3 with a 3918-nt GU insertion was restricted in replication in the upper (fivefold) and lower (25-fold) respiratory
tracts of hamsters. Although a 1908-nt GU insertion did not significantly modify replication of wild-type PIV3 in vitro or in vivo,
its introduction significantly augmented the level of temperature sensitivity (ts) and attenuation (att) specified by three
mutations in the L protein of a cold-passaged attenuated PIV3 vaccine virus. rPIV3s bearing a 3126- or 3894-nt NCR insertion
exhibited in vitro and in vivo phenotypes like those of the rPIV3s bearing similar-sized GU insertions. These findings indicate
that rPIV3s whose genome length has been increased by more than 3000 nt by either a GU or an NCR insertion exhibit an
unexpected host-range phenotype, that is, efficient replication in vitro but restricted replication in hamsters, especially in the
lower respiratory tract. Furthermore, these effects were greatly enhanced when the rPIV3 backbone contained other ts or
att mutations. The implications of these findings for the use of single-stranded, negative-sense RNA viruses as vectors for
vaccines are discussed. © 2000 Academic Press
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The ability to recover infectious virus from cDNAs of
single-stranded, negative-sense RNA viruses belonging
to the Mononegavirales order of viruses, referred to as
mononegaviruses, has made it possible to explore the
use of these viruses as vectors for the expression of
foreign antigens for use as vaccines (Bukreyev et al.,
1996, 1999; Finke and Conzelmann, 1997; Hasan et al.,
1997; He et al., 1997; Jin et al., 1998; Johnson et al., 1997;
Kahn et al., 1999; Kretzschmar et al., 1997; Mebatsion et
al., 1996; Moriya et al., 1998; Roberts et al., 1998, 1999;
Roberts and Rose, 1998; Schnell et al., 1996a,b, 1997;
Singh and Billeter, 1999; Singh et al., 1999; Spielhofer et
l., 1998; Yu et al., 1997). When placed under the control
f viral transcription gene-start (GS) and gene-end (GE)
ignals and inserted into the gene order, the foreign
1 To whom reprint requests should be addressed at NIH, Building 7,
oom 100, 7 Center Drive, MSC 0720, Bethesda, MD 20892-0720. Fax:
301) 496-8312. E-mail: mskiadopoulos@niaid.nih.gov.
225ene is expressed as a separate mRNA, and a high level
f protein expression occurs.
One concern that has arisen for the use of mononega-
iruses as vectors is that foreign gene expression can
ecrease replication in vitro, complicating the production
f vaccine virus. Certain foreign proteins appear to be
oxic and indirectly decrease viral replication, such as in
he case of VSV expressing the influenza virus NA or the
easles virus F protein (Kretzschmar et al., 1997; Schnell
et al., 1996a). More generally, the insertion of an addi-
tional gene can decrease the efficiency of transcription
of downstream genes. An increase in genome length,
independent of the number of transcriptional units, also
might reduce the efficiency of virus growth. For example,
Sendai virus-bearing gene inserts ranging in size from
0.7 kb up to 3.2 kb was partially defective for replication
in vitro and in vivo (Sakai et al., 1999). The degree of
impairment was in direct proportion to the size of the
protein expressed, but it was not determined whether
this was a function of the expressed protein or the size of
the gene or both.
0042-6822/00 $35.00
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226 SKIADOPOULOS ET AL.Here we examined several aspects of the use of re-
combinant human PIV3 as a vector of foreign sequence.
Infection by PIV3 in infancy or early childhood can result
in severe lower respiratory tract disease and is a signif-
icant cause of hospitalization due to respiratory illness in
infants (Collins et al., 1996). There is, therefore, a clear
eed for a PIV3 vaccine. PIV3 is an enveloped virus that
ontains a single-stranded, negative-sense RNA genome
5462 nt in length. The 39 and 59 ends of the viral genome
ontain extragenic leader and trailer regions that pos-
ess promoters required for replication and transcription.
he PIV3 genetic map is 39 leader-N-P(C/D/V)-M-F-HN-
-59 trailer. Transcription initiates at the 39 end and pro-
eeds by a sequential stop-start mechanism that is
uided by short conserved motifs found at the gene
oundaries. The upstream end of each gene contains a
S signal, which directs initiation of its respective
RNA. The downstream terminus of each gene contains
GE motif, which directs polyadenylation and termina-
ion, and each gene is separated by a conserved inter-
enic trinucleotide that also is thought to play a role in
ranscription (Collins et al., 1996).
A number of attributes make PIV3 an attractive choice
s a vector for heterologous antigens: (1) our ability to
ecover infectious PIV3 from cDNA (Durbin et al., 1997),
2) the availability of attenuated derivatives of PIV3 that
re currently in clinical trials (Karron et al., 1995b; Ski-
dopoulos et al., 1998, 1999a,b), (3) the ability of an
ttenuated PIV3 vaccine candidate to replicate in the
espiratory tract, in the presence of physiological
mounts of maternally acquired antibodies (Durbin et al.,
999a), (4) the induction of strong systemic and local
mmune responses by PIV3 (Durbin et al., 1999a), and (5)
he availability of an antigenic chimeric PIV3 bearing the
IV1 F and HN protective antigens (Skiadopoulos et al.,
999c; Tao et al., 1998). A cold passaged (cp) PIV3,
ermed cp45, has been shown to be safe and immuno-
enic in humans (Belshe and Hissom, 1982; Karron et al.,
995a,b), and its use as a vector to immunize against an
dditional human pathogen would be practical, because
series of rPIV3s bearing various combinations or all of
he cp45 mutations has been described (Skiadopoulos et
l., 1999a) and is immediately available for constructing
ttenuated PIV3 derivatives.
In our effort to explore the use of PIV3 as a vector, we
irst sought to define the relative contribution of the
ength of a transcription unit on virus replication in vitro
nd in vivo. The gene unit (GU) insertions of various
engths containing GS and GE sequences were engi-
eered to lack a significant open reading frame (ORF),
hich permitted an evaluation of the effect of GU length
n replication independent of an effect of an expressed
rotein. Control viruses bearing 39 noncoding region
NCR) insertions that increased the length of the genome
ithout increasing the total number of transcriptional
nits were also evaluated. These rPIV3s with GU or NCRnsertions were evaluated for rate and level of replication
n vitro, for level of temperature sensitivity of plaque
ormation in vitro, and for their level of replication in the
pper and lower respiratory tracts of hamsters.
RESULTS
onstruction of cDNAs encoding rPIV3 viruses
ontaining GU or NCR inserts of increasing lengths
A series of rPIV3s was designed that contained inserts
f increasing length of sequence derived from a heter-
logous virus, RSV (Fig. 1, Table 1). One type of insert
designated GU) was designed so that the foreign se-
uence was flanked by PIV3 GS and GE transcription
ignals to form a gene unit that would encode an addi-
ional mRNA (Fig. 1A). The GU inserts were placed be-
ween the HN and L genes. To distinguish between
ffects due to increased genome length versus the syn-
hesis of an additional mRNA, a second type of insert
designated NCR) was designed. These inserts did not
ontain transcription signals and were placed in the
ownstream 39 NCR of the HN gene in the same site
sed for the GU inserts (Fig. 1B). Thus the number of
ncoded mRNAs was unchanged, although the down-
tream NCR of the HN mRNA was increased in size. The
oreign sequence was inserted in an orientation such
hat all reading frames contained multiple stop codons
o that a functional protein could not be produced. Be-
ause the inserted RSV sequence was designed to lack
significant ORF, phenotypic differences resulting from
he insertion could be attributed to the length of the
nsert and not to an effect of an expressed protein on
irus replication. The GU inserts ranged in size from 168
o 3918, whereas the NCR inserts ranged from 258 to
894 nt. In all cases, the final antigenome length was a
ultiple of six, conforming to the rule of six.
The use of rPIV3 as a vector might require the inclu-
ion of attenuating mutations in the PIV3 backbone. We
herefore inserted a 1908-nt GU into rcp45L, which en-
codes three amino acid changes in the L protein that
confer the temperature sensitivity (ts) and attenuation
(att) phenotypes (Skiadopoulos et al., 1998), and we eval-
uated the effect of the insertion on these phenotypes.
The 1908-nt GU insert was chosen because its size is
representative of many paramyxovirus glycoprotein
genes.
Recovery of rPIV3 and evaluation in vitro
The various antigenomic cDNAs were used to direct
the recovery of rPIV3 as described previously. In each
case, rPIV3 was recovered successfully. In initial ampli-
fication, the various rPIV3s grew to similar titer (note that
the viruses were recovered and propagated at 32°C,
which is a permissive temperature for each virus). RNA
was isolated from each recovered virus and analyzed by
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227LONG NUCLEOTIDE INSERTIONS BETWEEN REGIONS OF rPIV3RT–PCR to confirm the presence of an insert of the
appropriate size in genomic RNA (Fig. 2). In addition, the
RT–PCR products were analyzed by restriction enzyme
digestion and partial nucleotide sequencing to confirm
genome structure. Also, the presence of the three ts
mutations in rcp45L was confirmed (not shown). Thus
rPIV3 containing an NCR or a GU insert of up to 3894 and
3918 nt in length, respectively, representing more than
25% of the 15642-nt wild-type (wt) PIV3 genome, was
viable and grew efficiently in vitro.
The multistep growth kinetics of representative rPIV3
viruses were evaluated (Fig. 3). In Fig. 3A, wt rPIV3 was
compared with rPIV3 bearing GU inserts of 168, 1908,
and 3918 nt. The mutant viruses replicated with kinetics
FIG. 1. Location and construction of GU or NCR insertions. The downs
site at antigenomic positions 8598–8603, which was then used to const
intergenic (IG), and GS signal sequences] are indicated. (A) For GU
sequences, as well as the unique restriction enzyme recognition seque
fragment from an RSV antigenome plasmid was cloned into the HpaI s
site of the multiple cloning site, so that the total length of the insert wou
to 3918 nt. Note that rPIV3 containing a GU insert would encode an addi
containing MluI, HpaI, BstBI, and SacI restriction sites was cloned into
sequence and synthetic oligonucleotides as described above and indic
Note that rPIV3 containing an NCR insert would encode an HN mRNA w
be unchanged.similar to that of wild-type virus, although the peak titer of
r3918 GU insert was sixfold lower than rPIV3 wt. Figure
N
t3B shows a comparison of the growth of wt rPIV3 and
two attenuated recombinant viruses, namely rcp45L, and
its derivative, rcp45L, bearing the 1908-nt GU insert. In-
sertion of the 1908 GU did not decrease the rate of
replication of rcp45L, but the peak titer of rcp45L/1908
was sixfold lower than that of rcp45L. Figure 3C com-
ares rPIV3 wt with rPIV3s bearing NCR inserts of 258,
404, and 3845 nt. The kinetics of replication of rPIV3 wt
nd rPIV3s bearing the NCR inserts were similar, and the
eak titer of the rPIV3 3845 NCR insertion mutant was
nly fivefold less than that of rPIV3 wt.
Next, the wild-type and mutant viruses were evaluated
or their efficiency of plaque formation over a range of
emperatures (Table 2). At 32°C, rPIV3 bearing GU or
(39) NCR of the PIV3 HN gene was modified to contain a StuI restriction
and NCR inserts. Cis-acting transcriptional signal sequences [i.e., GE,
an oligonucleotide duplex specifying the HN GE, IG, and GS signal
re shown inserted into the introduced StuI restriction site. A restriction
necessary, a short oligonucleotide duplex was inserted into the MluI
form to the rule of six. The final size of the GU inserts ranged from 168
RNA of increasing size. (B) For NCR inserts, an oligonucleotide duplex
uI site, and the HpaI and MluI sites were used to accept RSV-specific
Table 1. The final size of the NCR inserts ranged from 258 to 3894 nt.
CR was of increasing length, but the number of encoded mRNAs wouldtream
ruct GU
inserts,
nces, a
ite. As
ld con
tional m
the St
ated inCR inserts of varying sizes had plaque morphologies
hat were the same as that of wt rPIV3. For the rPIV3
t
i
n
p
a
v
i
t
R
i
e
CGCGG
228 SKIADOPOULOS ET AL.bearing GU inserts, the efficiency of plaque formation
was undiminished at 39°C or 40°C, but at both temper-
atures, the GU viruses produced small plaques (Table 2).
This phenotype did not appear to be dependent on the
size of the insert. Unexpectedly, rPIV3 bearing NCR in-
serts of 1404 nt or larger exhibited a ts phenotype. Also,
the rPIV3/NCR viruses exhibited a small plaque pheno-
type at 39°C and 40°C. Another unexpected finding was
that insertion of the 1908-nt GU into rcp45L reduced its
iter at 37°C and 38°C by at least 100-fold. Thus the
nsertion of foreign sequence conferred a slight ts phe-
otype to rPIV3 wt, evident by either small plaque mor-
T
Sources of Nucleotides Used t
Restriction fragment
size (nt)
Restriction sites and nt po
in the RSV antigenom
97a SspI–SspI; 7272–7369
212b HpaI–HpaI; 12243–12455
603b SspI–SspI; 309–912
925b HpaI–HpaI; 12455–13380
1356b,c HincII–HincII; 5060–6417
1850b,d HpaI–HpaI; 12455–13380
3079b EcoRV–Ecl136II; 1403–44
3845b ScaI–ScaI; 344–4189
a Source of RSV sequence is pUC118FM2, a plasmid containing a su
t al., 1997).
b Source of RSV sequence is D53sites, a plasmid containing the ent
(Whitehead et al., 1998).
c The gel-purified 1356-nt fragment contained a 1-nt deletion compa
d The 1850-nt fragment is a product of two 39-to-39 adjoined 925 nt
e Total size of each GU or NCR insertion includes the indicated RSV
polycloning site of NCR inserts, and as necessary an oligonucleotide 13
of six. Where required, one of following oligonucleotides was inserted
genome to be a multiple of six: 13 mer, CGCGGCAGGCCTG; 14 mer,
CTCCGCGG; 17 mer, CGCGAGGCCTCCGCGGG.
FIG. 2. The genomic RNAs of recovered rPIV3 mutants contain
inserts of the appropriate size. RT–PCR was performed using a PIV3-
specific primer pair flanking the insertion site, and RT–PCR products
were separated by agarose gel electrophoresis. The expected size of
the RT–PCR fragment for rPIV3 wt is 3497 bp, and that for each of the
other rPIV3 GU or NCR mutants is increased in length depending on the
size of the insertion. M, HindIII restriction enzyme digestion products of
lambda phage DNA. Sizes of relevant size markers are indicated. (A)
GU insertion mutants. Lane 1, rPIV3 wt; lane 2, r168-nt GU insert; lane
2, r678-nt GU insert; lane 3, r996-nt GU insert; lane 4, r1428-nt GU insert;
lane 5, r1908-nt GU insert; and lane 6, r3918-nt GU insert. (B) NCR
insertion mutants. Lane 1, rPIV3 wt; lane 2, r258-nt NCR insert; lane 3,i
a
r972-nt NCR insert; lane 4, r1404-nt NCR insert; lane 5, r3126-nt NCR
insert; and lane 6, r3894-nt NCR insert.hology or reduction in plaque formation at 39–40°C,
nd augmented the level of temperature sensitivity of a
irus bearing ts and att mutations. It was therefore of
nterest to examine the phenotype of these rPIV3 inser-
ion mutants in vivo.
eplication of rPIV3 containing a GU or an NCR
nsertion in hamsters
Hamsters were inoculated intranasally (i.n.) with 106.0
TCID50 of wt rPIV3, rcp45L, or a mutant rPIV3 bearing a
GU insertion (Table 3). Lungs and nasal turbinates were
harvested on day 4 after infection, and the level of rep-
lication of each virus was determined. Insertion of a GU
ranging in size from 168 nt up to 1908 nt did not signifi-
cantly reduce viral replication in the respiratory tract of
hamsters. However, insertion of a 3918-nt gene unit be-
tween the HN and L ORF of wt PIV3 resulted in a 5- and
25-fold reduction in viral replication in the nasal turbi-
nates and lungs, respectively. This indicates that GU
insertions of this size attenuate wild-type virus, whereas
shorter sizes have little effect on replication of wild-type
virus in the respiratory tract of hamsters. Thus GU length
is determinant of attenuation in vivo.
The r1908-nt GU ins/cp45L, in which the 1908-nt GU
insertion was combined with the cp45L polymerase
amino acid substitutions, was 20-fold more attenuated in
the upper respiratory tract of hamsters (Table 3) than its
rcp45L parent virus. Considered together, these findings
te the GU and NCR Insertions
GU insertion
(total nt insertede)
NCR insertion
(total nt insertede)
168 —
— 258
678 —
996 972
1428 1404
1908 —
— 3126
3918 3894
ic cDNA fragment of RSV subgroup A as described previously (Juhasz
subgroup A cDNA sequence with several introduced point mutations
h the predicted 1357-nt restriction endonuclease cleavage product.
on fragments.
ce, 58 bases in the polycloning site of GU inserts, or 32 bases in the
ses in length to conform the total number of inserted bases to the rule
e MluI restriction site to adjust the length of the insert and that of the
CGAGGCCTG; 15 mer, CGCGAGGCCTCCGCG; 16 mer, CGCGAGGC-ABLE 1
o Crea
sition
e
82
bgenom
ire RSV
red wit
restricti
sequen
–17 ba
into thndicate that GU insertions of 3918 nt in length can
ttenuate a wild-type PIV3 virus for hamsters and that a
ST
229LONG NUCLEOTIDE INSERTIONS BETWEEN REGIONS OF rPIV3GU insertion half this size can augment the attenuation
phenotype of a PIV3 vaccine candidate.
Hamsters were also inoculated i.n. with rPIV3 wt,
rcp45L, or a virus bearing an NCR insertion mutation
FIG. 3. Multistep growth curves of rPIV3 GU and NCR insertion
mutants. LLC-MK2 monolayers were infected in triplicate with the
indicated rPIV3 at a multiplicity of infection of 0.01 at 32°C. Aliquots of
the medium supernatants were harvested at 24-h intervals and as-
sayed at 32°C for virus titer and are shown as mean log10 TCID50/ml.
he lower limit of detection is 1.7 log10 TCID50/ml. (A) GU insertions. (B)
rcp45L/1908 GU insertion. (C) NCR insertions.(Table 4). Lungs and nasal turbinates were harvested 4
days after inoculation, and the level of viral replication ineach tissue was determined as described above. NCR
insertions ranging in size from 258 nt up to 1404 nt did
not significantly reduce viral replication in the respiratory
tract of hamsters. However, an insertion of 3126 nt ef-
fected a 16-fold reduction in both the upper and lower
respiratory tracts of infected hamsters, and a 3894-nt HN
gene NCR insertion resulted in a 12-fold reduction of viral
replication in the upper and lower respiratory tracts,
suggesting that increasing the genome length may also
have an attenuating effect on viral replication in vivo.
DISCUSSION
Mononegaviruses are potentially useful as vectors for
several reasons. First, in most cases the inserts remain
stably expressed even after many passages in vitro
(Bukreyev et al., 1999; Mebatsion et al., 1996; Schnell et
al., 1996a). This differs from findings with single-
stranded, positive-sense RNA viruses in which the in-
serts are subject to deletion (Mattion et al., 1994; Pu-
gachev et al., 1995). Insert stability is important for a
vaccine virus because extensive replication is required
for vaccine production. Second, in most cases mono-
negaviruses have accepted relatively large inserts with-
out drastic reduction in replication (Johnson et al., 1997;
Sakai et al., 1999; Spielhofer et al., 1998). Third, attenu-
ated derivatives of certain mononegaviruses are avail-
able and thus represent safe vectors (Karron et al.,
1995a,b; Singh et al., 1999; Skiadopoulos et al., 1999c;
pielhofer et al., 1998; Whitehead et al., 1998). Specific
examples of mononegavirus vectors include (1) vesicular
stomatitis virus, an animal virus, that can express the
hemagglutinin (HA) or neuraminidase (NA) protein of
influenza A virus, the HA or F protein of measles virus, or
gp160 of human immunodeficiency virus (Johnson et al.,
1997; Kretzschmar et al., 1997; Roberts et al., 1999;
Schnell et al., 1996a, 1997) and (2) measles virus, a
human virus, that can express hepatitis B virus antigens
(Singh and Billeter, 1999; Singh et al., 1999). Finally, the
mononegavirus selected to be a vector can also be a
human pathogen, in which case immunity would be in-
duced against the vector, as well as the expressed in-
sert. This is illustrated by the above example of the
measles vector expressing hepatitis B virus antigens.
An ideal mononegavirus vector would be an attenu-
ated vaccine virus into which one or more foreign genes
expressing protective antigens of another virus could be
inserted without affecting its replication in vitro or its
level of attenuation and immunogenicity. This ideal vec-
tor would be able to accept a variety of viral protective
antigens, and its safety and immunogenicity would be
predictable. Unfortunately, experience to date with
mononegavirus vectors indicates that such an ideal vec-
tor has not yet been identified, because foreign gene
insertions can result in decreased replication of the
vector virus in vitro or in vivo depending on the size of the
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230 SKIADOPOULOS ET AL.insert or the specific protein that is expressed (Johnson
et al., 1997; Kretzschmar et al., 1997; Roberts et al., 1999;
akai et al., 1999; Schnell et al., 1996a, 1997). Insertions
hat decrease replication in vitro could decrease the
ommercial feasibility of the vaccine and might render
he vaccine virus overattenuated and poorly immuno-
enic. The present findings do not identify an ideal
ononegavirus vector, but they do provide a framework
T
Efficiency of Plaque Formation of rPIV3 GU and NCR Inse
Virus
V
32°C
rPIV3 wt 7.8
r168-nt GU insert 7.8
r678-nt GU insert 7.9
r996-nt GU insert 7.7
r1428-nt GU insert 7.8
r1908-nt GU insert 7.6
r3918-nt GU insert 6.3
r258-nt NCR insert 8.1
r972-nt NCR insert 8.2
r1404-nt NCR insert 6.7
r3126-nt NCR insert 7.4
r3894-nt NCR insert 7.4
rcp45L 7.8
r1908-nt GU insert/cp45L 6.7
rcp45 8.1
a Plaques were enumerated by immunoperoxidase staining after in
epresent the lowest restrictive temperature at which there was a leas
emperature of plaque formation.
b Small plaques compared with plaque size at 32°C.
TABLE 3
Replication of rPIV3 GU Insertion Mutants in the Respiratory Tract
of Hamsters
Virusa
Mean virus titer
(log10TCID50/g 6 SEM) in:
Nasal turbinates Lungs
rPIV3 wt 5.9 6 0.2 [A]b 6.0 6 0.2 [A]b
r168-nt GU insert 5.9 6 0.1 [A]b 6.4 6 0.1 [A]b
r678-nt GU insert 6.1 6 0.1 [A] 6.2 6 0.1 [A]
996-nt GU insert 5.5 6 0.2 [A] 5.4 6 0.2 [A]
1428-nt GU insert 5.9 6 0.1 [A] 5.3 6 0.6 [A]
1908-nt GU insert 5.6 6 0.1 [A] 5.7 6 0.2 [A]
3918-nt GU insert 5.2 6 0.2 [B] 4.6 6 0.3 [B]
cp45L 3.1 6 0.0 [C] 1.7 6 0.2 [C]
1908-nt GU insert/cp45L 1.8 6 0.2 [D] 1.5 6 0.0 [C]
a Hamsters in groups of eight were administered 106.0 TCID50 of virus
per animal i.n. in a 0.1-ml inoculum. Lungs and nasal turbinates were
harvested 4 days later, and virus titer was determined at 32°C.
b Mean values in each column with a different letter are significantly
different (a 5 0.05) by Tukey-Kramer test, whereas those with the same
etter are not significantly different. lor understanding some of the factors that affect the
eplication of the vector in vitro and in vivo and that
should be considered in the design and in the preclinical
and clinical evaluation of mononegavirus vectors.
Previous observations clearly indicated that the in vitro
or in vivo replication of mononegavirus vectors could be
substantially modified by the expression of specific pro-
teins (Kretzschmar et al., 1997; Sakai et al., 1999; Schnell
et al., 1996a). Thus for any expressed foreign protective
antigen, one must determine the consequences of its
utants at Permissive and Non-Permissive Temperaturesa
r at indicated temperature (log10pfu/ml)
38°C 39°C 40°C
ND 7.4 7.5
ND 7.5b 6.7b
ND 7.3b 7.0b
ND 7.0b 6.3b
ND 7.4b 6.4b
ND 6.5b 6.0b
ND 5.7b 5.0b
ND 7.4b 7.5b
ND 7.8b 7.8b
ND 5.2b ,3.7
ND 6.4b 4.5b
ND 5.3b 5.0b
6.0 ,0.7 ND
3.0b ,0.7 ND
5.7b 2.0a ND
on for 6 days at the indicated temperature. Values that are in bold
-fold reduction of plaquing efficiency, which is defined as the shut-off
TABLE 4
Replication of rPIV3 NCR Insertion Mutants in the Respiratory Tract
of Hamsters
Virusa
Mean virus titer
(log10TCID50/g 6 SEM) in:
Nasal turbinates Lungs
rPIV3 wt 6.2 6 0.1 [A]b 6.4 6 0.1 [A]b
r258-nt NCR insert 5.9 6 0.1 [A] 6.5 6 0.1 [A]
r972-nt NCR insert 5.9 6 0.1 [A] 6.6 6 0.1 [A]
r1404-nt NCR insert 5.9 6 0.2 [A] 6.6 6 0.1 [A]
r3126-nt NCR insert 5.0 6 0.1 [B] 5.2 6 0.1 [B]
r3894-nt NCR insert 5.1 6 0.1 [B] 5.3 6 0.1 [B]
rcp45L 3.4 6 0.1 [C] 1.9 6 0.2 [C]
a Hamsters in groups of eight were administered 106.0 TCID50 of virus
per animal i.n. in a 0.1-ml inoculum. Lungs and nasal turbinates were
harvested 4 days later, and virus titer was determined at 32°C.
b Mean values in each column with a different letter are significantlyABLE 2
rtion M
irus tite
37°C
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
7.3
5.0b
6.7
cubati
t a 100different (a 5 0.05) by Tukey-Kramer test, whereas those with the same
etter are not significantly different.
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231LONG NUCLEOTIDE INSERTIONS BETWEEN REGIONS OF rPIV3expression on in vitro and in vivo replication. We have
xtended these findings by demonstrating that the length
f a GU insertion, regardless of the protein expressed,
an also make an independent contribution to attenua-
ion. Thus insert size as well as the specific protein
xpressed must be taken into consideration in the eval-
ation of mononegavirus vectors. Specifically, insertion
f a 3918-nt GU between the HN and L ORF of wt PIV3
esulted in a 5- and 25-fold reduction in viral replication
n the nasal turbinates and lungs, respectively, indicating
hat GU insertions of this size are attenuating for a
ild-type virus. This level of restriction in replication in
he lower respiratory tract of hamsters was greater than
hat seen in vitro. The basis for attenuation specified by
U insertion remains to be determined. Because NCR
nsertions of the same size were also attenuating in and
f themselves, it is possible that an increase in PIV3
enome length, rather than a disruption of the normal
ranscriptional gradient that occurs on insertion of a GU,
as the major determinant of the decreased replication
f the PIV3 vector in vivo. Both the GU and NCR inser-
ions affected replication in vivo to a greater extent than
n vitro. Thus insertion of noncoding sequences into the
enome of a mononegavirus can be added to the list of
ypes mutations that can attenuate these viruses in vivo
Collins et al., 1999; Nagai and Kato, 1999).
Unexpectedly, insertion of a GU of approximately 1.9
kb, which did not significantly affect the replication of wt
PIV3 in vivo, augmented both the ts and att phenotypes of
he attenuated PIV3 cp45L candidate vaccine. Thus the
ttenuating effect of an insertion into an attenuated virus
an be significantly greater than that observed when the
ame insert is introduced into wild-type virus.
Considered together, these observations indicate that
he consequences of constructing any given recombi-
ant mononegavirus vector vaccine remains highly em-
irical and that each vaccine candidate must be individ-
ally evaluated to determine whether it exhibits both
fficient replication in vitro and the desired balance be-
ween attenuation and immunogenicity. Despite these
onstraints, the ability of rPIV3 to accommodate long
eterologous sequence and the availability of attenuated
erivatives of rPIV3, as well as attenuated rPIV3/PIV1
ntigenic chimeric viruses, make this PIV vector system
otentially useful for rapidly creating and evaluating mul-
ivalent vaccines capable of inducing an immune re-
ponse to the PIV backbone itself as well as to the
ectored foreign antigen.
MATERIALS AND METHODS
iruses and cells
The rPIV3 JS wt and rcp45L viruses that were used as
ontrols in this study were generated previously (Durbin
t al., 1997; Skiadopoulos et al., 1998). The rPIV3s were
grown in simian LLC-MK2 cells [American Type Culture eCollection (ATCC) CCL 7.1] as described previously
(Durbin et al., 1997; Hall et al., 1992; Skiadopoulos et al.,
1998). The modified vaccinia virus Ankara (MVA-T7)
(Wyatt et al., 1995), which expresses the T7 polymerase,
was kindly provided by Linda Wyatt and Bernard Moss.
HEp-2 (ATCC CCL 23) and LLC-MK2 cells were main-
tained in OptiMEM I (Life Technologies, Gaithersburg,
MD) supplemented with 5% FBS and gentamicin sulfate
(50 mg/ml).
onstruction of cDNAs encoding rPIV3 viruses
ontaining GU or NCR insertions
Insertion mutations were constructed in a pUC-based
lasmid, pUC118-Stu, containing an StuI restriction en-
onuclease recognition sequence introduced at nt 8598–
603 in the XhoI-to-SphI fragment (PIV3 nt 7437–11317) of
he full-length PIV3 clone p3/7(131)2G-Stu. The StuI site
as introduced by mutating the AGACAA present in the
9 NCR of the HN gene to AGGCCT by site-directed
utagenesis. Two separate plasmids were constructed
s acceptor plasmids for the insertion of GUs and HN
ene 39-NCR extensions (Fig. 1). In each, a synthetic
ligonucleotide duplex containing multiple cloning sites
as inserted into the unique StuI site. The inserted
equence for the GU insertion plasmid contained an HN
E signal sequence, the conserved intergenic (IG) trinu-
leotide sequence, and an L GS signal sequence, cis-
cting sequences that direct termination of the HN gene
ranscription and initiation of transcription of the inserted
equence (Fig. 1A). Additional unique restriction endo-
uclease sites were included in the multiple cloning
egion to facilitate subsequent screening and subclon-
ng. The 39-NCR extension acceptor plasmid was simi-
arly designed and constructed, but it lacked the cis-
cting GE, IG, and GS sequences at its 59-end (Fig. 1B).
s a source of foreign sequence, the RSV antigenomic
lasmid d53RSVsites (Whitehead et al., 1998) or sub-
enomic plasmid pUC118FM2 (Juhasz et al., 1997) (Table
) was digested with the appropriate restriction en-
ymes, and fragments of the desired sizes were isolated
y electrophoresis on agarose gels and ligated individ-
ally into the unique HpaI site of the GU or NCR exten-
ion acceptor plasmid (Fig. 1; Table 1). Clones were
creened to identify those in which the RSV restriction
ragments were inserted in the reverse orientation in
hich all reading frames contain multiple stop codons.
hort synthetic oligonucleotide duplexes ranging in size
rom 13 to 17 nt also were inserted as necessary into the
luI site of the GU or NCR constructs to modify the
enome length to conform to the rule of six (Collins et al.,
996) (Fig. 1). The specific RSV sequences and size of
he short synthetic oligonucleotides added are summa-
ized in Table 1.Plasmid clones were sequenced through all restriction
nzyme sites used for subcloning, and the XhoI–SphI
p
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232 SKIADOPOULOS ET AL.fragments containing the GU or NCR inserts were cloned
into the full-length PIV3 wild-type cDNA plasmid p3/
7(131)2G1 (Durbin et al., 1997). In addition, the 1908 GU
insert was placed into an antigenomic cDNA bearing the
three ts and att L mutations of cp45 (Skiadopoulos et al.,
1998).
Recovery of rPIV3s bearing GU and NCR inserts
Full-length antigenomic cDNAs each bearing a GU or
an NCR insertion were transfected together with the
three support plasmids pTM(N), pTM(P no C), and
pTM(L) (Durbin et al., 1997, 1999b) into HEp-2 monolay-
ers in 6-well plates (Costar, Cambridge, MA) using Lipo-
fectACE (Life Technologies, Gaithersburg, MD), and the
monolayers were infected with MVA-T7 as described
previously (Durbin et al., 1997; Skiadopoulos et al., 1998).
After incubation at 32°C for 4 days, the transfection
harvest was passaged onto LLC-MK2 cells in T-25 flasks
that were incubated at 32°C for 4–8 days. The clarified
medium supernatant was subjected to plaque purifica-
tion on LLC-MK2 cells as described previously (Durbin et
al., 1997; Hall et al., 1992; Skiadopoulos et al., 1998). Each
biologically cloned recombinant virus was amplified
twice in LLC-MK2 cells at 32°C to produce virus for
further characterization. Virus was concentrated from
clarified medium by polyethylene glycol precipitation
(Mbiguino and Menezes, 1991), and viral RNA (vRNA)
was extracted with Trizol Reagent (Life Technologies).
Reverse transcription was performed on vRNA using the
Superscript II Preamplification System (Life Technolo-
gies) with random hexamer primers. The Advantage
cDNA PCR kit (Clontech, Palo Alto, CA) and sense (PIV3
nt 7108–7137) and antisense primers (PIV3 nt 10605–
10576) were used to amplify PCR fragments that were
analyzed by agarose gel electrophoresis and by se-
quencing (data not shown).
Efficiency of plaque formation of mutant rPIV3s at
permissive and restrictive temperatures
The level of temperature sensitivity of plaque forma-
tion in vitro of control and recombinant viruses was
determined at 32°C and at a range of temperatures from
35°C to 40°C in LLC-MK2 monolayer cultures incubated
for 6 days as previously described (Hall et al., 1992;
Skiadopoulos et al., 1998). Plaques were enumerated by
immunoperoxidase staining with a mixture of two PIV3-
specific anti-HN murine monoclonal antibodies 101/1
and 454/11 diluted 1:250 (Murphy et al., 1990; van Wyke
Coelingh et al., 1985), and titers are expressed as log10
plaque-forming units (PFU)/ml.
Evaluation of rPIV3 mutant viruses for the att
phenotype in hamstersFour-week-old Golden Syrian hamsters (Charles River
Laboratories, NY) that were seronegative for PIV3 wereinoculated i.n. with 0.1 ml of L15 medium containing 106.0
TCID50 of wt rPIV3 or one of the mutant rPIV3s. On day 4
ostinfection, the lungs and nasal turbinates were har-
ested, and the virus was quantified as previously de-
cribed (Skiadopoulos et al., 1998). The mean
og10TCID50/g at 32°C was calculated for each group of
hamsters.
Multicycle growth curves
Each PIV3 was inoculated in triplicate into LLC-MK2
monolayers in 6-well plates at a multiplicity of infection of
0.01, and cultures were incubated at 32°C, as described
previously (Tao et al., 1998). Then 0.5 ml of medium from
ach well was harvested and replaced with 0.5 ml of
resh medium at 0 and 24 h intervals thereafter for 6 days
ostinfection. Harvested samples were stored at 280°C.
irus present in the samples was quantified by TCID50 on
LLC-MK2 monolayers in 96-well plates and incubated at
32°C. Virus was detected by hemadsorption and re-
ported as mean log10TCID50/ml.
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